Thursday, 5 November 2026European Markets
ExploreSearch
ViaNews EU
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· October 16, 2026

ASUS ProArt P16 & P14, Powered by NVIDIA RTX Spark, Now Available for Purchase in the United States

View original at finance.yahoo.com

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Local execution eliminates per-token charges for everyday experimentation and iteration, and keeping models, prompts, source files and project data on device helps protect intellectual property and enables offline workflows.

    60% confidence

  • The ProArt P16 and P14 redefine personal computing as a new class of personal Windows PCs powered by NVIDIA RTX Spark.

    60% confidence

  • For users running intensive AI-agent workloads daily, cloud token costs may exceed the cost of a ProArt RTX Spark-powered PC within as little as five to ten months.

    60% confidence

  • The ProArt P16 and P14, with up to 1 petaflop of AI performance and up to 128GB of unified memory, can locally run large language and vision-language models, image and video generation pipelines, LoRA fine-tuning, agentic AI workflows and complex 3D scenes.

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Oncology Data Season and Biotech Capital Allocation: ESMO Readouts, Ivonescimab PDUFA, and Diverging Corporate Moves
Late-2026 biotech is driven by a dense catalyst calendar. ESMO 2026 delivers data from ivonescimab, Enhertu, R-DXd and bemarituzumab, and the FDA has set a 14 Nov PDUFA date for the ivonescimab BLA. Capital allocation is diverging. Krystal Biotech authorized a $400M buyback while lowering FY2026 spend guidance and pushing milestones into 2027. Spago is moving to delist from Nasdaq First North. The facts are clinical and corporate events, not AI or fintech, so the finance angle is limited to capital markets (buybacks, guidance, delistings, regulatory timelines).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,549 source documents archived
Query this data → isubstrate.com